Table 1. General Characteristics of Patients.
| Characteristic | Overall Cohort (N = 193) |
|---|---|
| Age, mean (SD), y | 64 (11) |
| BMI, median (IQR) | 24.0 (21.5-27.0) |
| <25 | 131 (67.9) |
| ≥25 | 62 (32.1) |
| Sarcopenia, No. (%) | 84 (43.5) |
| Sex, No. (%) | |
| Male | 97 (50.3) |
| Female | 96 (49.7) |
| Stage at diagnosis, No. (%) | |
| Borderline resectable | 63 (32.6) |
| Locally advanced | 130 (67.4) |
| NT scheme, No. (%) | |
| FOLFIRINOX | 124 (64.2) |
| PAXG/PEXG | 54 (28.0) |
| Gemcitabine based | 15 (7.8) |
| Tumor size, mean (SD), mm | |
| Pre-NT | 33.4 (13.4) |
| Post-NT | 25.8 (13.51) |
| Radiologic response, No. (%) | |
| Stable disease | 127 (65.8) |
| Partial or complete | 51 (26.4) |
| Progressive disease | 15 (7.8) |
| Months from diagnosis to surgery, median (IQR) | 6 (4-7) |
| Resection, No. (%) | |
| No. | 57 (29.5) |
| Yes | 136 (70.5) |
| Vascular resection, No. (%) | 19 (14.0) |
| Category at pathologic examination, No. (%) | |
| Tx | 7 (5.1) |
| T1-T2 | 25 (18.4) |
| T3 | 100 (73.5) |
| T4 | 4 (2.9) |
| Nodal involvement, No. (%) | |
| N0 | 82 (60.3) |
| N1 | 54 (39.7) |
| Negative resection margins (R0), No. (%) | 92 (67.6) |
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); FOLFIRINOX, combined fluorouracil, irinotecan, oxaliplatin, leucovorin, and folic acid; PEXG, combined cisplatin, epirubicin, capecitabine, and gemcitabine; IQR, interquartile range; NT, neoadjuvant treatment; PAXG, combined cisplatin, capecitabine, gemcitabine, and nanoparticle albumin–bound paclitaxel.